APRE Aprea Therapeutics Inc - Ordinary Shares

26.05
+1.89  (+8%)
Previous Close 24.16
Open 25
Price To Book -7.73
Market Cap 546,802,577
Shares 20,990,502
Volume 209,729
Short Ratio
Av. Daily Volume 106,960
Stock charts supplied by TradingView

NewsSee all news

  1. Aprea Therapeutics Reports Third Quarter 2019 Financial Results

    BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

  2. Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting

    BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

  3. Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    BOSTON, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 enrolment to be completed 1H 2020.
APR-246 and azacitidine
Myelodysplastic syndromes (MDS)/Acute myeloid leukemia (AML) Post-Transplant Trial
Phase 2 data to be presented at ASH December 9, 2019 at 11:15 am ET.
APR-246 and azacitidine
Myelodysplastic syndromes (MDS)
Phase 3 initial data due 2H 2020.
APR-246 and azacitidine
TP53 mutant Myelodysplastic syndromes (MDS)
Phase 2 data to be presented at ASH December 9, 2019.
APR-246 and azacitidine
TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)

Latest News

  1. Aprea Therapeutics Reports Third Quarter 2019 Financial Results

    BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

  2. Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting

    BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

  3. Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    BOSTON, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor